专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010041837A2 A USE OF THE LIQUIRITIGENIN ABUNDANT EXTRACT OR LIQUIRITIGENIN DERIVED THEREFROM FOR INCREASING BILE FLOW, CHOLERETIC EFFECT, AND FOR PREVENTING AND TREATING CHOLESTATIC LIVER DISEASES 审中-公开
标题翻译：使用液态碘甘油富含提取物或源于此的提取液以增加胆汁流动，促进胆碱性效应以及预防和治疗胆汁淤积性肝病
公开(公告)号：WO2010041837A2
公开(公告)日：2010-04-15
申请号：PCT/KR2009/005451
申请日：2009-09-24
申请人： SNU R&DB FOUNDATION , KIM, Sang Geon , KIM, Sang Chan , KIM, Young Woo
发明人： KIM, Sang Geon , KIM, Sang Chan , KIM, Young Woo
IPC分类号： A61K36/484
CPC分类号： A61K36/484
摘要： The present invention is related to a composition comprising an extract of licorice or liquiritigenin derived therefrom, which significantly increases bile flow rate and biliary excretion of bile acid, GSH and bilirubin. Consistent with these results, the inventive composition comprising an extract of licorice or liquiritigenin derived therefrom decrease the blood chemical markers including ALT as a hepatoprotective marker, and ALP and γ-GTP, as cholestatasis markers, and histochemical markers including central necrosis and inflammation in galactosamine/lipopolysaccharide-induced hepato-toxicity animal model when the inventive extract or compound of the present invention was orally and intravenously administrated thereto.
摘要翻译：本发明涉及包含由其衍生的甘草或甘草提取物的组合物，其显着增加胆汁酸流速和胆汁酸，GSH和胆红素的胆汁排泄。与这些结果一致，包含由其衍生的甘草或甘草甜素提取物的本发明组合物降低血液化学标记，包括作为肝保护性标记的ALT和作为胆汁淤积标记的ALP和γ-GTP，以及包括中央坏死和半乳糖胺炎症的组织化学标记 /脂多糖诱导的肝毒性动物模型，当将本发明的本发明提取物或化合物口服和静脉内施用于其上时。

2. 发明申请

WO2007081115A1 COMPOSITION COMPRISING LIQUIRITIGENIN FOR PREVENTING AND TREATING LIVER DISEASE 审中-公开
标题翻译：包含用于预防和治疗肝病的液体组合物的组合物
公开(公告)号：WO2007081115A1
公开(公告)日：2007-07-19
申请号：PCT/KR2007/000081
申请日：2007-01-05
申请人： SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION , KIM, Sang Geon , KIM, Sang Chan , KIM, Young Woo
发明人： KIM, Sang Geon , KIM, Sang Chan , KIM, Young Woo
IPC分类号： A61K36/484 , A61K31/352 , A23L1/29 , A61P1/16
CPC分类号： A61K36/484 , A23L33/10 , A23L33/105 , A23V2002/00 , A61K31/352 , A23V2250/28 , A23V2250/0644 , A23V2250/21 , A23V2250/032
摘要： The present invention is related to a composition comprising an extract of licorice or liquiritigenin isolated therefrom significantly decrease the blood concentration of LDH and ALT enzymes, central necrosis and inflammation in toxicant-induced hepato-toxicity animal model when the inventive extract or compound of the present invention was orally and intravenously administrated thereto.Accordingly, the inventive compositions according to the present invention are useful in the prevention and treatment of the liver diseases and can be used as safe and efficient hepato-protective.
摘要翻译：本发明涉及包含甘草或甘草素的提取物的组合物，当本发明的本发明提取物或本发明的提取物或化合物在本发明的提取物或化合物中时，显着降低了LDH和ALT酶的血液浓度，毒性诱导的肝毒性动物模型中的中枢坏死和炎症本发明的本发明组合物可用于预防和治疗肝脏疾病，并可用作安全有效的肝保护剂。

3. 发明申请

WO2010016681A2 PHARMACEUTICAL COMPOSITION CONTAINING 1,2-DITHIOLTHIONE DERIVATIVE FOR PREVENTING OR TREATING DISEASE CAUSED BY OVEREXPRESSION OF LXR-ALPHA 审中-公开
标题翻译：含有1,2-二硫醇衍生物的药物组合物用于预防或治疗由LXR-ALPHA过表达引起的疾病
公开(公告)号：WO2010016681A2
公开(公告)日：2010-02-11
申请号：PCT/KR2009/004242
申请日：2009-07-30
申请人： SNU R&DB FOUNDATION , KIM, Sang Geon , KI, Sung Hwan , HWANG, Seong Hwan
发明人： KIM, Sang Geon , KI, Sung Hwan , HWANG, Seong Hwan
IPC分类号： A61K31/385
CPC分类号： A61K31/385
摘要： Provided is a pharmaceutical composition that contains a 1,2-dithiolthionederivative, and is effective to prevent and treat a disease caused by overactivity of a liver X receptor α (LXR α ) or a sterol response element binding protein (SREBP-1). Specifically, the pharmaceutical composition includes 1,2-dithiolthione derivatives such as 4-methyl-5-(2-pyrazinyl)-1,2-dithiol-3-thione, 3-methyl-1,2-dithiol-3-thione, or 5-(6-methoxypyrazinyl)-4-methyl-1,2-dithiol-3-thione. The pharmaceutical composition is effective for preventing and treating hypertension caused by renin, aldosteronism, adrenoleukodystrophy, glomerulosclerosis, proteinuria, nephropathy, liver steatosis, hypertriglyceridemia or hyperreninemia.
摘要翻译：本发明提供一种含有1,2-二硫醇硫酮衍生物的药物组合物，该组合物可有效预防和治疗由肝X受体α（LXRα）的过度活性或甾醇应答元件结合引起的疾病蛋白质（SREBP-1）。具体而言，药物组合物包括4-甲基-5-（2-吡嗪基）-1,2-二硫醇-3-硫酮，3-甲基-1,2-二硫醇-3-硫酮等1,2-二硫醇硫酮衍生物，或5-（6-甲氧基吡嗪基）-4-甲基-1,2-二硫醇-3-硫酮。该药物组合物对于预防和治疗由肾素，醛固酮症，肾上腺脑白质营养不良，肾小球硬化，蛋白尿，肾病，肝脂肪变性，高甘油三酯血症或高血压症引起的高血压是有效的。

4. 发明申请

WO2011122805A2 A COMPOSITION COMPRISING AJOENE FOR PREVENTING OR TREATING A DISEASE CAUSED BY OVEREXPRESSION OF LXR-ALPHA 审中-公开
标题翻译：包含用于预防或治疗由LXR-ALPHA过表达引起的疾病的AJOENE的组合物
公开(公告)号：WO2011122805A2
公开(公告)日：2011-10-06
申请号：PCT/KR2011/002094
申请日：2011-03-25
申请人： SNU R&DB FOUNDATION , KIM, Sang Geon , RYU, Jae Ha , JEON, Ra Ok , HAN, Chang Yeob
发明人： KIM, Sang Geon , RYU, Jae Ha , JEON, Ra Ok , HAN, Chang Yeob
IPC分类号： A61K36/8962 , A61P1/16 , A61P9/12 , A61P3/00
CPC分类号： A61K36/8962
摘要： The present invention is related to a composition comprising the ajoene -abundant garlic extract or ajoene isolated therefrom as an active ingredient for treating or preventing the disease caused by over-expression or hyper-activation of LXR-alpha or SREBP-1, together with a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及一种组合物，其包含从其中分离出来的富含大蒜的大蒜提取物或邻苯二甲酸酯作为活性成分，用于治疗或预防由LXR-α或SREBP-1的过度表达或超激活引起的疾病，以及药学上可接受的载体。

5. 发明申请

WO2008066353A1 PHARMACEUTICAL COMPOSITION COMPRISING METADOXINE AND GARLIC OIL FOR PREVENTING AND TREATING ALCOHOL-INDUCED FATTY LIVER AND STEATOHEPATITIS 审中-公开
标题翻译：包含元二氧化氮和甘油的药物组合物用于预防和治疗酒精诱导的脂肪肝和血清蛋白
公开(公告)号：WO2008066353A1
公开(公告)日：2008-06-05
申请号：PCT/KR2007/006162
申请日：2007-11-30
申请人： SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION , KIM, Sang Geon , KI, Sung Hwan , CHOI, Jae Hoon
发明人： KIM, Sang Geon , KI, Sung Hwan , CHOI, Jae Hoon
IPC分类号： A61K31/4439
CPC分类号： A61K31/4439 , A61K36/63 , A61K2300/00
摘要： The present invention relates to a pharmaceutical or food or drink composition for preventing or treating alcohol-induced fatty liver or steatohepatitis comprising metadoxine (pyridoxol l-2-pyrrolidone-5- carboxylate) and garlic oil as active ingredients. The concurrent administration of metadoxine and garlic oil according to the present invention exhibits outstandingly superior effects of inhibiting the accumulation of triglyceride and increase of blood AST (aspartate aminotransferase) level in liver tissue, inhibiting the expression of FAS (fatty acid synthase), CYP2E1 and iNOS (inducible nitric oxide synthase) and inhibiting the deactivation of AMPK (AMP-activated protein kinase), as compared to the administration of metadoxine or garlic oil only. Therefore, the composition of the present invention can be useful in preventing or treating alcohol -induced fatty liver and steatohepatitis caused by alcohol intake or in improving or restoring the liver function damaged by alcohol intake.
摘要翻译：本发明涉及用于预防或治疗醇诱导的脂肪肝或脂肪性肝炎的药物或食品或饮料组合物，其包含偏头痛（吡哆醇-2-吡咯烷酮-5-羧酸酯）和大蒜油作为活性成分。根据本发明并用给药的异多昔啡和大蒜油显示出显着优异的抑制甘油三酯积累和增加肝组织中AST（天冬氨酸转氨酶）水平的作用，抑制FAS（脂肪酸合成酶），CYP2E1和与仅使用偏二氢ine啶或大蒜油相比，iNOS（诱导型一氧化氮合酶）和AMPK（AMP活化蛋白激酶）的失活抑制。因此，本发明的组合物可用于预防或治疗由酒精摄入引起的酒精诱导的脂肪肝和脂肪性肝炎，或用于改善或恢复由酒精摄入损伤的肝功能。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式